Dashboard
Manage Tickers

ICCMIceCure Medical Ltd.

Nasdaq icecure-medical.com


$ 0.72 $ -0.01 (-0.98 %)    

Wednesday, 21-Aug-2024 15:05:25 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 0.7472
$ 0.74 x 300
$ 0.75 x 300
-- - --
$ 0.52 - $ 1.57
1,179,695
na
34.17M
$ 11.26
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-icecure-medical-lowers-price-target-to-25
HC Wainwright & Co. Maintains Buy on Icecu...
08/21/2024 11:53:35

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from ...

icecure-medical-q2-2024-gaap-eps-006-beats-007-estimate-sales-101m-beat-92550k-estimate
Icecure Medical Q2 2024 GAAP EPS $(0.06) B...
08/20/2024 12:39:16

Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.0...

icecure-medical-reports-h1-eps-of-014--up-from-017-last-year
IceCure Medical Reports H1 EPS Of $(0.14),...
08/20/2024 12:36:26

icecure-says-the-study-concluded-that-most-non-surgical-patients-with-early-stage-breast-cancer-accepted-cryoablation-when-the-treatment-was-offered-and-that-cryoablation-is-a-safe-effective-alternative-to-surgery-and-well-tolerated-as-an-out-patient-procedure
IceCure Says The Study Concluded That 'Mos...
08/14/2024 12:34:08

icecure-medical-announces-publication-of-independent-study-titled-acceptance-and-results-of-cryoablation-for-the-treatment-of-early-breast-cancer-in-non-surgical-patients-in-british-journal-of-radiology
IceCure Medical Announces Publication Of I...
08/14/2024 12:33:20

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100%Study ...

icecure-medical-announces-publication-of-independent-study-in-american-journal-of-roentgenology-study-shows-recurrence-free-rates-of-947-878-and-818-at-1-2-and-3-years-in-higher-risk-breast-cancer-patients-using-cryoablation
IceCure Medical Announces Publication Of I...
08/07/2024 12:36:13

Core News & Articles
IceCure Medical Presents Key Findings On P...
07/22/2024 12:33:32

icecure-medical-receives-receipt-from-nasdaq-minimum-bid-price-notification
IceCure Medical Receives Receipt From Nasd...
07/19/2024 20:31:14

IceCure Medical Ltd. (NASDAQ:ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destro...

icecure-medical-announces-independent-study-results-for-prosense-cryoablation-system-published-in-peer-reviewed-journal-cancers
IceCure Medical Announces Independent Stud...
07/09/2024 12:36:22

Study Shows High Complete Ablation Rate And Satisfactory Overall Survival In Breast Cancer Patients; Conducted At University Ho...

hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Icec...
07/02/2024 10:30:56

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

us-fda-grants-regulatory-clearance-to-icecure-for-next-gen-xsense-cryoablation-system-with-cryoprobes
U.S. FDA Grants Regulatory Clearance To Ic...
07/01/2024 12:33:23

IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minima...

why-nurix-therapeutics-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket
Why Nurix Therapeutics Shares Are Trading ...
06/17/2024 12:43:16

icecure-medical-reports-data-from-its-kidney-cancer-clinical-study-presented-at-interventional-radiology-conference-dsud-minimally-invasive-approach-results-in-shorter-hospitalization-and-minor-impact-on-renal-function
IceCure Medical Reports Data From Its Kidn...
06/12/2024 12:32:55

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors w...

hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Icec...
06/05/2024 11:34:54

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

icecure-medical-announces-fda-advisory-panel-meeting-to-review-prosense-system-for-tumor-cryoablation
IceCure Medical Announces FDA Advisory Pan...
06/04/2024 12:35:23

hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Icec...
05/29/2024 10:21:32

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

icecure-medical-q1-eps-008-inline-sales-74300k-miss-87550k-estimate
Icecure Medical Q1 EPS $(0.08), Inline, Sa...
05/28/2024 12:45:33

Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is ...

icecure-is-expected-to-receive-a-total-of-132m-in-proceeds-from-terumo-during-this-initial-term-of-which-it-has-received-4m-to-date-with-an-additional-82m-expected-upon-the-completion-of-orders-as-well-as-1m-expected-for-milestone-based-payments
IceCure Is Expected To Receive A Total Of ...
05/07/2024 12:45:12

independent-study-results-in-japan-demonstrate-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-data-published-globally
Independent Study Results In Japan Demonst...
05/07/2024 12:45:06

Study published in the peer reviewed journal Breast CancerExcellent cosmetic outcomes, high degree of patient satisfaction, and...

hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Icec...
04/16/2024 15:03:56

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION